Search results
May 1, 2024 · Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. He has spent over a decade specializing in founding, building and investing in biotech companies. Aaron was a founding board member of Tourmaline Bio (Nasdaq: TRML), Centessa Pharmaceuticals, and RayzeBio, which was recently acquired by Bristol Myers Squibb.
Apr 27, 2024 · Prior to the closing of the financing transaction, Samantha Truex and Aaron Kantoff are expected to be appointed to Avalo’s Board of Directors. The five existing Avalo directors will continue...
Apr 21, 2024 · The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors. Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. He has spent over a decade specializing in founding, building and investing in biotech companies.
Apr 17, 2024 · Aaron Kantoff is a founder and Managing Partner of Scion Life Sciences. He has spent over a decade specializing in founding, building and investing in biotech companies. Aaron was a founding board member of Tourmaline Bio (Nasdaq: TRML), Centessa Pharmaceuticals, and RayzeBio, which was recently acquired by Bristol Myers Squibb.
6 days ago · The list of insiders at Centessa Pharmaceuticals includes Aaron Kantoff, Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Karen M Anderson, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman, and Tia L Bush.
- 345 N Reid Place, Suite 620, Sioux Falls, 57103, SD
- contact@marketbeat.com
- (844) 978-6257
4 days ago · Insiders that own company stock include Aaron Kantoff, Caley Castelein, Mark Mcdade, Parvinder Thiara and Sandeep Chidambar Kulkarni. View institutional ownership trends . How do I buy shares of Tourmaline Bio?
Apr 30, 2024 · AVTX.O. Latest Trade. 17.12 USD. 0.24. +1.42% As of Apr 30, 2024. Values delayed up to 15 minutes. Today's Range. 16.01 - 17.15. 52 Week Range. 3.95 - 1,130.40. Profile. Charts. Financials. Key...
